B4V.F Arcticzymes Technologies ASA

Healthcare Biotechnology Frankfurt Exchange
2.11 EUR
Close of Nov 11, 2026
1.54 2.15
Market cap
EUR 108M
P/E
105.5x
P/B
3.15x
ROE
2.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is B4V.F undervalued?

Graham number

The Graham number of Arcticzymes Technologies ASA cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arcticzymes Technologies ASA fundamental analysis

No fundamental analysis for Arcticzymes Technologies ASA yet.

Arcticzymes Technologies ASA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arcticzymes Technologies ASA

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents…

Full company profile